VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma

Inclusion Criteria: * Stage IIIB, IIIC, IIID histologically-proven melanoma. * Cancer confirmed to be surgically resectable, with surgery evaluation with planned prior to resection. * No prior immunotherapy with cytotoxic T-lymphocyte associated protein-4 (CTLA-4), anti programmed cell death-1 (PD-1) or VX15/2503. Prior interferon (at least 1 year prior to consent) will be allowed. * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1. * Absolute neutrophil count ≥ 1,500 cells/µL. * Platelets ≥ 100,000/µL. * Hemoglobin ≥ 9.0g/dL (may receive packed red blood cells \[PRBC\] transfusion). * Total bilirubin ≤ 1.5 x the upper limit of normal (ULN). * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN. * Albumin ≥ 3.0 g/dL. * Serum creatinine ≤ 1.5 x ULN OR calculated creatinine clearance of ≥ 50 mL/min using Cockcroft-Gault formula. * International normalized ration (INR) ≤ 1.5. Anticoagulation is allowed only with low molecular weight heparin (LMWH). Patient receiving LMW heparin on stable therapeutic dose for more than 2 weeks or with factor Xa level \< 1.1 U/mL are allowed on the trial. * Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures. * Ability to understand and willingness to sign a written informed consent document. * Female subjects of childbearing potential must agree to use adequate contraception (at least one highly effective method and one addition…